US backs waiving intellectual property rules for Covid-19 vaccines

US Trade Representative Katherine Tai testifies during a Senate hearing in Washington on April 28, 2021. (AP file photo)

The Biden administration is throwing its support behind efforts to waive intellectual property protections for COVID-19 vaccines in an effort to speed the end of the pandemic.

United States Trade Representative Katherine Tai announced the government's position in a Wednesday statement, amid World Trade Organisation talks over easing global trade rules to enable more countries to produce more of the life-saving vaccines.

"The administration believes strongly in intellectual property protections, but in service of ending this pandemic, supports the waiver of those protections for COVID-19 vaccines," Tai said in the statement.

But she cautioned that it would take time to reach the required global "consensus" to waive the protections under WTO rules, and US officials said it would not have an immediate effect on the global supply of COVID-19 shots.

"This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures," said Tai.

"The administration's aim is to get as many safe and effective vaccines to as many people as fast as possible," she said.

Tai's announcement comes hours after WTO Director-General Ngozi Okonjo-Iweala spoke to a closed-door meeting of ambassadors from developing and developed countries that have been wrangling over the issue, but agree on the need for wider access to COVID-19 treatments, WTO spokesman Keith Rockwell said.

ALSO READ: China halting flights to India could hurt pharma supplies, say companies

 

The WTO's General Council -- made up of ambassadors -- was taking up the pivotal issue of a temporary waiver for intellectual property protections on COVID-19 vaccines and other tools, which South Africa and India first proposed in October.

The idea has gained support in the developing world and among some progressive lawmakers in the West.

Rockwell said a WTO panel on intellectual property was set to take up the waiver proposal again at a tentative meeting later this month, before a formal meeting June 8-9.

No consensus -- which is required under WTO rules -- was expected to emerge from the ambassadors' two-day meeting Wednesday and Thursday. But Rockwell pointed to a change in tone after months of wrangling.

"I would say that the discussion was far more constructive, pragmatic. It was less emotive and less finger pointing than it had been in the past, Rockwell said, citing a surge in cases in places like India.

"I think that this feeling of everyone-being-in-it-together was being expressed in a way that I had not heard to this point."

Authors of the proposal, which has faced resistance from many countries with influential pharmaceutical and biotech industries, have been revising it in hopes of making it more palatable.

Okonjo-Iweala, in remarks posted on the WTO website, said it was incumbent on us to move quickly to put the revised text on the table, but also to begin and undertake text-based negotiations".

"I am firmly convinced that once we can sit down with an actual text in front of us, we shall find a pragmatic way forward, that is "acceptable to all sides," she said.

 

Co-sponsors of the idea were shuttling between different diplomatic missions to make their case, according to a Geneva trade official who was not authorized to speak publicly on the matter. A deadlock persists, and opposing sides remain far apart, the official said.

The argument, part of a long-running debate about intellectual property protections, centres on lifting patents, copyrights and protections for industrial design and confidential information to help expand the production and deployment of vaccines during supply shortages.

The aim is to suspend the rules for several years, just long enough to beat down the pandemic.

The issue has become more pressing with a surge in cases in India, the world's second-most populous country and a key producer of vaccines, including one for COVID-19 that relies on technology from Oxford University and British-Swedish pharmaceutical maker AstraZeneca.

Proponents, including WHO Director-General Tedros Adhanom Ghebreyesus, note that such waivers are part of the WTO toolbox and insist there's no better time to use them than during the once-in-a-century pandemic that has taken 3.2 million lives, infected more than 437 million people and devastated economies.

More than 100 countries have come out in support of the proposal, and a group of 110 members of Congress -- all fellow Democrats of Biden -- sent him a letter in April that called on him to support the waiver.

Opponents say a waiver would be no panacea. They insist that production of coronavirus vaccines is complex and simply can't be ramped up by easing intellectual property, and say lifting protections could hurt future innovation.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel